Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.
Meloxicam is well absorbed after oral administration, with an absolute bioavailability of 89% that is not markedly affected by concomitant intake of food. Meloxicam reaches maximum plasma ...
A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results